At last check, the stock price of PLx Pharma Inc. (PLXP) was at $18.99, up 5.03% in after-hours trading yesterday. PLx Pharma stock fell -3.47% on Monday, closing the day at $18.08. PLx Pharma stock traded for 0.24 million on the day, which is lower than the average volume over the last three months of 516.90K. A trading range of $18.02 and $19.03 was observed for the PLXP stock during the trading session. PLXP had earnings per share ratio of -2.52.
In the past five sessions, the price of PLx Pharma stock fell -7.19 percent, and over the past one month, it fell 32.55%, but it gained 227.54% year-to-date. PLx Pharma stock’s 50-day moving average of $15.01 is above its 200-day moving average of $9.05. Further, PLXP’s stock is trading at 57.14 on an RSI basis. News of a nationwide distribution of its lead drug sent PLXP stock surging.
How will PLXP Stock make this possible?
PLx Pharma manufactures drug delivery platforms that provide better safety and efficacy with its clinically validated and patent-protected PLxGuard drug delivery technology. As part of its PLxGuard drug delivery system, PLx Pharma targets active pharmaceutical ingredients to specific locations along the gastrointestinal tract (GI). By developing this platform, PLXP believes that several drugs currently on the market or under development can improve absorption and reduce ulcers and stomach erosions associated with some drugs.
Three Stock Keeping Units (“SKUs”) of PLX Pharma’s VAZALORE, the first and only US Food and Drug Administration (“FDA”)-approved liquid-filled aspirin capsules, will be available at nearly 8,000 CVS stores end of this month. As compared to enteric-coated aspirin, VAZALORE by PLXP is a compound infused with liquid to provide patients with vascular disease, as well as diabetics who are candidate for aspirin therapy fast, reliable, and predictable platelet inhibition.
PLx Pharma drug also improves stomach lining, compared to immediate-release aspirin commonly used in an acute setting. The leading health solutions company CVS is preparing its retail space by displaying ‘Coming Soon’ placeholders and shelf trays. All three SKUs are included: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. CVS announced that it will carry PLXP’s innovative aspirin product nationwide as PLXP continues to launch its VAZALORE product. The focus of CVS on patient care aligns well with the mission of PLXP to provide VAZALORE to millions of patients.
Similar moves by PLXP:
PLx Pharma (PLXP) made the Vitazolore product available in over 2,400 Rite Aid stores this month after making the three different types of Vitazolore available. The nationwide launch of PLXP’s VAZALORE includes CVS joining Walmart, Walgreens, Rite Aid, and other retailers.
